OBJECTIVE: This study investigated the antitumour effects of intermediate frequency alternating electric fields (IF-AEF) in a murine melanoma cell line (B16F10) and a mouse tumour model. METHODS: IF-AEF was applied at 100 kHz. Proliferation of B16F10 cells in vitro was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. IF-AEF was applied in vivo to mice bearing B16F10 tumours. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay for apoptosis, and immunohistochemical detection of CD34 and vascular endothelial growth factor (VEGF), were performed. RESULTS: IF-AEF inhibited the proliferation of B16F10 cells in an electrical intensity and time-dependent manner. Treatment with IF-AEF for 7 days significantly inhibited the growth of tumours compared with untreated controls. IF-AEF induced apoptosis in vivo and reduced CD34-positive cell numbers; CD34 is a special marker of microvessel density. CONCLUSION: IF-AEF reduced microvessel density related to tumour growth and may serve as a therapeutic strategy for cancer treatment.
Introduction
Alternating electric fields have many biological applications including drug delivery, cancer therapy and immune stimulation. 1 -4 It has been shown that the biological effects of alternating electric fields are closely linked to parameters of both the electric field and the cells involved, 3, 5 with the frequency of the alternating electric field being a major factor. 1, 4 Low frequency (< 1 kHz) and high frequency (> 1000 kHz) alternating electric fields have been widely studied. There is, however, limited research regarding intermediate frequency (100 -1000 kHz) alternating electric fields (IF-AEF), since it is believed that fields of ≥ 100 kHz have no meaningful biological effects. 6 Some studies have reported the effects of IF-AEF (100 -1000 kHz) on malignant tumours, 1, 7 but the mechanism of these effects is not well H Chen, R Liu, J Liu et al.
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understood. Reported effects of IF-AEF include the arrest of cell proliferation, sensitization of tumour cells to chemotherapy and regulation of immune function. 1, 8 A functioning vascular supply is essential for the continued growth of solid tumours, which would otherwise remain dormant. 9 The therapeutic potential of interfering with the vasculature is both widely recognized and highly promising. Nanosecond pulsed electric fields have been shown to reduce tumour blood supply, 10 but other researchers have found that electric fields can induce angiogenesis. 11 The aim of the present study was to determine whether IF-AEF could alter tumour blood supply. Suspensions of a murine melanoma cell line (B16F10) and subcutaneously induced tumours were exposed to IF-AEF, and the effects on apoptosis and angiogenesis were investigated.
Materials and methods

B16F10 CELL CULTURE
The murine melanoma cell line (B16F10) was obtained from the Institute of Basic Medical Science, Chinese Academy of Medical Science, Beijing, China. Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin, in a humidified environment with 5% carbon dioxide at 37°C. Cells between passages five and 10 were used in the experiment and were not allowed to reach > 75% confluency. Before treatment, cells were harvested by trypsinization and resuspended in supplemented DMEM as described above.
MOUSE TUMOUR MODEL
Animal care and experimentation was carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (http://oacu. od.nih.gov/regs/guide/guide4.htm). Male C57BL/6 mice (6 -8 weeks old, median age 6.9 weeks) weighing 18 -22 g (median weight 21 g) were purchased from the Animal Centre of the Beijing Genetics Research Institute, Beijing, China. Mice were housed at room temperature (21 ± 1°C) in a relative humidity of 45 ± 15%, in sterile cages (n = 10 animals per cage) with free access to standard food and water in a 12-h light/12-h dark cycle. All mice were acclimatized for 7 -10 days in one of the animal rooms at Tsinghua University before being used. B16F10 cells were digested with 0.25% trypsin and resuspended at 1 × 10 7 cells/ml in 100 mM phosphate-buffered saline (PBS), pH 6.8. Cell suspensions (2 × 10 6 cells in 0.2 ml of PBS) were injected subcutaneously into the right flank of the mice. Immediately following inoculation, the mice were randomly divided into two groups of 10 animals, according to a computer-generated randomization schedule, for electric field treatment or control treatment. Ten animals per group were chosen, due to the limitations of the IF-AEF apparatus.
IN VITRO IF-AEF STIMULATION
Sine wave IF-AEF was generated by a pulse generator (Department of Engineering Physics, Tsinghua University, Bejing, China) consisting of a pulse-forming network, a switch and the load ( Fig. 1 ). Electric fields were generated by two sterilized, parallel, insulated plate electrodes (50 mm × 15 mm × 1.5 mm, covered by insulating paint) fixed to the bottom of 54 mm disposable Petri dishes at a distance of 10 mm apart. B16F10 cells were plated by smearing 1 ml of DMEM containing 2 × 10 5 cells onto the Petri dish, along the gap between the electrodes. Electric H Chen, R Liu, J Liu et al.
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fields were then applied by connecting the electrodes to the pulse generator. Based on previous studies, 7 the frequency was identified at 100 kHz. The IF-AEF parameters of peak to peak voltage (Vpp) and exposure time were analysed in order to determine whether any effects were electrical intensity or time-dependent, respectively. The duration of exposure was limited to 48 h, due to cell crowding-related reduction in cell division after 3 days of culture. Control cells were held under identical conditions, but without the application of electric fields. After exposure, plated samples were harvested and the cells were incubated in supplemented DMEM for 24 h at 37°C, prior to undertaking the 3-(4,5-di methylthiazol-2yl)-2,5-diphenyltetra zolium bromide assay, a methyl thiazolyl tetrazolium cell proliferation assay, which was carried out using a commercially available kit (Beijing Biodee Biotechnology Co. Ltd, Beijing, China).
IN VIVO IF-AEF STIMULATION
At 2 days after inoculation, animals in the treatment group and in the control group were attached to two parallel insulated electrodes (gap 20 mm) so that the target tumour tissue was positioned between the electrodes ( Fig. 1 ). From 2 days after inoculation, animals in the IF-AEF group underwent stimulation with IF-AEF (sinusoidal waveform 100 kHz, Vpp 30 V) twice a day for 4 h (total 8 h). The treatment was continued for 7 days, consecutively. Animals in the control group underwent sham treatment, following the same schedule. Tumours were measured with a vernier calliper using the two mutually orthogonal tumour diameters (maximal and minimal diameter) every 3 days after treatment, i.e. on days 1, 4 and 7 after treatment. Tumour volume (V) was calculated using the standard formula: V = 0.5a × b 2 , where a is the longest diameter of the tumour and b is the longest diameter perpendicular to diameter a.
After 7 days, two mice from each group were sacrificed, the tumours were excised and samples were collected and processed immediately for histopathological and immunohistochemical examination. To observe the survival rate, the remaining 
HISTOLOGICAL ANALYSIS OF TUMOUR TISSUE
Tumour samples were fixed in 10% buffered formalin, embedded in paraffin wax and cut into 4-µm thick sections. Tumour sections were stained with haematoxylin and eosin (H&E) using standard histological techniques. In order to determine the effect of IF-AEF on healthy tissue, H&E staining was also performed on tissue from the ileum and colon of mice from both groups. These tissue samples were harvested at the same time as the tumour tissue.
IMMUNOHISTOCHEMICAL ANALYSIS OF CD34 AND VEGF PROTEIN
Tissue sections were prepared as described above. Microvessel density was identified by staining tissue sections with an antimouse CD34 antibody, as described previously, 12 -15 and vascular endothelial growth factor (VEGF) protein levels were assessed. Briefly, tissue sections were deparaffinized in xylene and rehydrated in an ethanol series, according to standard procedures. The slides were rinsed in 0.05 mM Tris-buffered saline (TBS), pH 7.6, for ≥ 15 min and antigen retrieval was achieved by microwaving for 10 min in 0.01 M citrate buffer (pH 6.0). To block endogenous peroxidase activity, the sections were incubated with 0.75% hydrogen peroxide solution in methanol for 30 min at room temperature, then rinsed with tap water and washed twice with 0.05 mM TBS for 5 min. To improve antibody penetration, the sections were treated with 0.1% protease in 0.05 mM TBS for exactly 5 min at room temperature, and washed with 0.05 mM TBS for 15 min. To block nonspecific binding, the sections were incubated with 5% bovine serum albumin /0.05 mM TBS for 15 min. The sections were then incubated with either mouse anti-CD34 or anti-VEGF monoclonal antibodies (BD Biosciences, San Jose, CA, USA) for 1 h at room temperature. After careful washing in 0.05 mM TBS, the sections were incubated with a biotinylated rabbit antimouse secondary antibody (1:100 dilution; DAKO, Glostrup, Denmark) for 30 min at room temperature and then washed thoroughly in 0.05 mM TBS. Then, horse radish peroxidaseavidin/biotin complex (DAKO) was added for 30 min, the slides were washed in 0.05 mM TBS and the colour reaction was developed using diamino benzidine staining (Sigma-Aldrich, St Louis, MO, USA) for 7 min at room temperature. The slides were counterstained with H&E for 5 min according to conventional procedures. Finally, the sections were rinsed in tap water for approximately 10 min, dehydrated and mounted, following standard procedures.
Immunohistochemical staining for CD34 and VEGF was evaluated quantitatively. The level of CD34 staining was first examined using low magnification (× 40 and × 100) to identify the areas of the tumour with highest density of blood vessels (i.e. the areas with the highest levels of brown immuno histochemical staining). Then, at high magnification (× 200) the CD34-positive cell numbers in five fields of view were recorded and the mean ± SD value was taken. The level of VEGF protein was assessed quantitatively at × 200 magnification by measuring the optical density (OD) of the immunohistochemical staining by light microscopy with digital imaging, using ImagePro ® Plus software, version 6.0 (Media Cybernetics, Bethesda, MD, USA).
DETECTION OF APOPTOSIS IN TUMOUR TISSUE
Tissue sections were prepared as described H Chen, R Liu, J Liu et al.
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above.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay was performed using a commercial kit (Roche, Basel, Switzerland) according to the manufacturer's instructions.
Briefly, sections were deparaffinized, rehydrated and permeabilized by incubation with 100 µl proteinase K (BD Biosciences) for 15 min at 37°C. Labelling buffer was omitted from negative controls, and positive controls were obtained by digestion of the sections with DNase I (BD Biosciences) for 10 min at room temperature before the detection procedure. An epifluorescence microscope with a broad bandpass filter was used to view the red apoptotic nuclei against blue normal nuclei.
STATISTICAL ANALYSES
Statistical analyses were performed with SPSS ® statistical software, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . All in vitro experiments were repeated at least three times. Data are presented as mean ± SD. Statistical analyses were carried out by applying multivariate analysis of variance, followed by the one-sample t-test with Bonferroni adjustment for individual pairwise comparisons. Survival analysis was performed using the Kaplan-Meier method and compared using the log-rank test. A Pvalue < 0.05 was considered to be statistically significant.
Results
Treatment with IF-AEF (Vpp 30 V) inhibited the proliferation of B16F10 cells at 24 and 48 h ( Fig. 2A) . Cell growth in IF-AEF treated cells was significantly inhibited by 16.4 ± 1.8% after 24 h and 27.1 ± 3.5% after 48 h compared with controls (P < 0.05). There was also a significant difference in growth inhibition between the 24 and 48 h time points (P < 0.05; Fig. 2A ). IF-AEF inhibited cell growth in a Vpp-dependent manner. Growth inhibition at a Vpp of 10, 20 and 30 V was 4.4 ± 0.5%, 12.4 ± 1.5% and 27.1 ± 3.5% respectively. The difference between these three Vpp subgroups and untreated control cells was statistically significant, and there was also a statistically significant (P < 0.05) difference between each of the three Vpp subgroups (P < 0.05 for all comparisons; Fig. 2B ).
Mean ± SD tumour volume was significantly lower in treated animals compared with control animals (26.3 ± 9.8 versus 263.8 ± 107.3 mm 3 , P < 0.05). IF-AEF treatment significantly prolonged lifespan (mean ± SD 29.1 ± 3.7 days in the treatment group versus 23.6 ± 3.7 days for controls, P < 0.05; Fig. 3 ). All mice in the control group died within 30 days, whereas 40% (n = 4) of mice in the treatment group survived > 30 days (Fig. 3) .
Representative photomicrographs of TUNEL assay findings are shown in Fig. 4 . Tumours treated with IF-AEF exhibited significantly greater numbers of apoptotic cells than control tumours (31.7 ± 6.6% versus 4.5 ± 1.3%; P < 0.05). Histological exam ination of normal ileum and colon tissue sections revealed no significant damage caused by IF-AEF treatment.
Representative photomicrographs of immunohistochemistry for CD34 and VEGF are shown in Fig. 5 and Fig. 6 , respectively. IF-AEF treatment significantly reduced the number of CD34-positive cells compared with controls (mean ± SD positive cells per field of view, 13.5 ± 3.0 versus 23.4 ± 5.5, respectively; P < 0.05). IF-AEF treatment also signficantly reduced the level of VEGF protein compared with that found in the control group (mean ± SD OD, 9860 ± 3154 versus 25620 ± 4985, respectively; P < 0.05).
Discussion
The IF-AEF exhibits direct and indirect (via H Chen, R Liu, J Liu et al.
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stimulation of the immune response) effects on tumour tissue. 1, 8 The present study examined the effects of IF-AEF on cell proliferation, apoptosis and angiogenesis in a murine melanoma cell line (B16F10) and in an in vivo murine tumour model. IF-AEF has an intensity-and time-dependent effect on cell proliferation in vitro, and inhibited tumour growth and extended survival in vivo. These findings are in accordance with previously published reports. 1, 5 Because of their important roles in tumour growth, the present study examined the effect of IF-AEF on mechanisms associated with apoptosis and angiogenesis. Previous studies have demonstrated the influence of electric field exposure on apoptosis, 2,4 and it is useful to consider the role of induction of apoptosis in the effect of IF-AEF. The present study found that IF-AEF induced apoptosis in B16F10 tumours in vivo. IF-AEF has the potential to be widely applied in clinical practice for the treatment of malignant melanoma, because the spontaneous 
apoptosis rate of melanoma cells is lower than that found in many other malignant tumours, 16 and melanoma is insensitive to chemotherapy induced apoptosis. 16 It is known that a functioning vascular supply is essential for the continued growth of solid tumours that would otherwise remain dormant. 9 An alternative approach to targeting the tumour itself is to target the stroma, in particular the blood vessel 17 -19 The objective of antiangiogenic therapies is to interfere with new vessel formation, resulting in insufficient delivery of nutrients and oxygen to tumour cells, with important con -sequences for tumour growth. 20, 21 The ability to modify local blood flow in tumours is, therefore, important for treatment. Different electric fields have different effects on angiogenesis, 3, 8 and the effects of IF-AEF on The process of new vessel development is extremely complex, and is reliant on a delicate balance of biochemical signals and receptors. 22 -24 The targeting of VEGF or its receptors with monoclonal antibodies (such as bevacizumab) or small-molecule inhibitors of VEGF receptor tyrosine kinase (such as ZD6474 and PTK787) has confirmed the anticancer activity of these agents. 25, 26 VEGF and CD34 were chosen in the present study as markers for the evaluation of the disruptive effects of IF-AEF on tumour vasculature. The microvessel density, as measured by the number of cells staining positive for CD34, and the level of VEGF protein in tumour tissues were significantly decreased in response to IF-AEF treatment. The decrease in CD34-positive cells in tumour tissue exposed to IF-AEF suggested that IF-AEF may cause a reduction in blood flow to solid tumours. It is possible that the inhibition of in vivo tumour growth observed in this study was due to a decrease in blood supply. IF-AEF may be useful for inhibiting key factors required for new vessel development, thereby reducing tumour growth. This is in accordance with previous findings that IF-AEF can inhibit metastatic spread of solid tumours to the lungs, 8 since angiogenesis is crucial for metastases.
Tumour treatment should ideally produce significant tumour cell death without damaging the surrounding normal tissue. No serious treatment-related toxicity on the ileum and colon, as shown by histological analyses, was found in any animal exposed to IF-AEF. In contrast to other angiogenesisdisrupting agents, the selectivity of IF-AEF is achieved by the local application of electrical pulses to the tumour, 20,27 thereby limiting its systemic toxicity.
The present study showed that IF-AEF inhibited the proliferation of B16F10 tumour cells in vitro and induced apoptosis in vivo. These data also provide evidence for the potential application of IF-AEF to disturb blood flow in tumours, thereby inhibiting tumour growth. A full understanding of these actions will provide insight into the mechanisms of IF-AEF and serve as the basis for the development of new antitumour therapies. IF-AEF may be a useful auxiliary method for tumour therapy with or without the addition of other, more traditional, therapeutic approaches. IF-AEF may provide a non scar-forming alternative to the surgical removal of skin lesions in melanoma. To develop this therapy further, it is necessary to understand the detailed mechanism of IF-AEF on cells both in vitro and in vivo, and their effects on both the cell membrane and intracellular organelles. At present, neither mechanism is fully understood and both warrant further investigation.
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